

## PAR6A RABBIT PAB

货号: S216713

产品全名: PAR6A 兔多抗

基因符号: PAR6; PAR6C; TAX40; PAR-6A; TIP-40; PAR6alpha

**UNIPROT ID:** Q9NPB6 (Gene Accession - BC015626)

**背景:** This gene is a member of the PAR6 family and encodes a protein with a PSD95/Discs-large/ZO1 (PDZ) domain and a semi-Cdc42/Rac interactive binding (CRIB) domain. This cell membrane protein is involved in asymmetrical cell division and cell polarization processes as a member of a multi-protein complex. The protein also has a role in the epithelial-to-mesenchymal transition (EMT) that characterizes the invasive phenotype associated with metastatic carcinomas. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

**抗原:** Fusion protein of human PAR6A

**经过测试的应用:** ELISA, IHC

**推荐稀释比:** IHC: 50-200; ELISA: 2000-5000

**种属反应性:** Rabbit

**克隆性:** Rabbit Polyclonal

**亚型:** Immunogen-specific rabbit IgG


**纯化:** Antigen affinity purification

**种属反应性:** Human, Mouse, Rat


**成分:** PBS (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**研究领域:** Signal Transduction, Epigenetics and Nuclear Signaling, Cancer, Stem Cells


**储存和运输:** Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human gastric cancer tissue using 216713(PARD6A Antibody) at a dilution of 1/60(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human gastric cancer tissue is first treated with the fusion protein and then with 216713(Anti-PARD6A Antibody) at dilution 1/60.



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using 216713(Anti-PARD6A Antibody) at a dilution of 1/60.



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with fusion protein and then with D221101(Anti-PARD6A Antibody) at dilution 1/60.



# Product Description

Pioneering GTPase and Oncogene Product Development since 2010

---